false 0001707502 0001707502 2022-03-30 2022-03-30












Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 30, 2022



Solid Biosciences Inc.

(Exact Name of Registrant as Specified in Charter)




Delaware   001-38360   90-0943402

(State or Other Jurisdiction

of Incorporation)



File Number)


(IRS Employer

Identification No.)

141 Portland Street, Fifth Floor

Cambridge, MA 02139

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (617) 337-4680

(Former Name or Former Address, if Changed Since Last Report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange

on which registered

Common Stock $0.001 par value per share   SLDB   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.




Item 5.05. Amendments to the Registrant’s Code of Ethics, or Waiver of a Provision of the Code of Ethics.

On March 30, 2022, the Board of Directors (the “Board”) of Solid Biosciences Inc. (the “Company”) approved a new Code of Business Conduct and Ethics (the “New Code of Conduct”). The New Code of Conduct is applicable to all employees, officers and directors of the Company and its subsidiaries. The New Code of Conduct replaces the Company’s previous Code of Business Conduct and Ethics (the “Prior Code”) in its entirety, to, among other things, reflect current industry and public company best practices. The New Code of Conduct also incorporates the procedures previously set forth in the Company’s Whistleblower Policy. The adoption by the Board of the New Code of Conduct did not result in any explicit or implicit waiver with respect to any employee, officer or director of the Company from any provision of the Prior Code. The New Code of Conduct became effective upon approval by the Board.

A copy of the New Code of Conduct is available on the Company’s website at https://investors.solidbio.com/governance/governance-documents. Information contained on the Company’s website is not incorporated by reference in, or considered part of, this Current Report on Form 8-K.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: April 4, 2022     By:  

/s/ Ilan Ganot


Name: Ilan Ganot

Title:   Chief Executive Officer